Elobixibat

Elobixibat
Clinical data
Routes of; administration	Oral
ATC code	None;
Identifiers
	IUPAC name N-{(2R)-2-[({[3,3-Dibutyl-7-(methylsulfanyl)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylacetyl}glycine;
CAS Number	439087-18-0;
PubChem CID	9939892;
DrugBank	DB12486;
ChemSpider	8115513;
UNII	865UEK4EJC;
KEGG	D10796 ;
ChEMBL	ChEMBL3039515;
CompTox Dashboard (EPA)	DTXSID00195985 ;
Chemical and physical data
Formula	C36H45N3O7S2
Molar mass	695.89 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)CNC(=O)[C@@H](c1ccccc1)NC(=O)COc4cc3c(N(c2ccccc2)CC(CS3(=O)=O)(CCCC)CCCC)cc4SC;
	InChI InChI=InChI=1S/C36H45N3O7S2/c1-4-6-18-36(19-7-5-2)24-39(27-16-12-9-13-17-27)28-20-30(47-3)29(21-31(28)48(44,45)25-36)46-23-32(40)38-34(26-14-10-8-11-15-26)35(43)37-22-33(41)42/h8-17,20-21,34H,4-7,18-19,22-25H2,1-3H3,(H,37,43)(H,38,40)(H,41,42)/t34-/m1/s1; Key:XFLQIRAKKLNXRQ-UUWRZZSWSA-N;

Elobixibat is an inhibitor of the ileal bile acid transporter (IBAT),[1] undergoing development in clinical trials for the treatment of chronic constipation and irritable bowel syndrome with constipation (IBS-C).

Mechanism of action

Elobixibat is an inhibitor of IBAT, which is an alternative name for the apical sodium bile acid transporter (ASBT) encoded by the SLC10A2 gene. ASBT/IBAT is a bile acid:sodium symporter responsible for the reuptake of bile acids in the ileum, the initial step in their enterohepatic circulation. By inhibiting the uptake of bile acids, elobixibat increases the bile acid concentration in the gut, and this accelerates intestinal passage and softens the stool. Following several phase II studies, it is now undergoing phase III trials.[2]

Drug development

The drug was developed by Albireo AB, who licensed it to Ferring Pharmaceuticals for further development and marketing.[3] Albireo has partnered with Ajinomoto Pharmaceuticals, giving the Japan-based company the rights to further develop the drug and market it throughout Asia.[4]

References

"INN for A3309 is ELOBIXIBAT". AlbireoPharma. Archived from the original on 18 January 2012. Retrieved 5 December 2012.
Acosta A, Camilleri M (2014). "Elobixibat and its potential role in chronic idiopathic constipation". Therap Adv Gastroenterol. 7 (4): 167–75. doi:10.1177/1756283X14528269. PMC 4107709. PMID 25057297.
Grogan, Kevin (4 July 2012). "Ferring acquires rights to Albireo's bowel drug". PharmaTimes. Retrieved 23 March 2017.
"Ajinomoto Pharmaceuticals and Albireo Announce Japan and Asia License Agreement for Elobixibat". Albireo. Archived from the original on 16 January 2013. Retrieved 5 December 2012.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[INNAlbi-1] "INN for A3309 is ELOBIXIBAT". AlbireoPharma. Archived from the original on 18 January 2012. Retrieved 5 December 2012.

[pmid25057297-2] Acosta A, Camilleri M (2014). "Elobixibat and its potential role in chronic idiopathic constipation". Therap Adv Gastroenterol. 7 (4): 167–75. doi:10.1177/1756283X14528269. PMC 4107709. PMID 25057297.

[3] Grogan, Kevin (4 July 2012). "Ferring acquires rights to Albireo's bowel drug". PharmaTimes. Retrieved 23 March 2017.

[AlbiAji-4] "Ajinomoto Pharmaceuticals and Albireo Announce Japan and Asia License Agreement for Elobixibat". Albireo. Archived from the original on 16 January 2013. Retrieved 5 December 2012.